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perspective was considered. We considered the following cost components: 
human resources, training, infrastructure, equipment and office supplies, trans-
portation, personal protective equipment (PPE), field and laboratory equipment, 
insecticides and social mobilization, considering capital and recurrent costs. 
Capital costs were estimated for both transmission periods combined. Results: 
The total and monthly recurring costs of the PMCD during the epidemic period 
was R$8.307.590 (US$4.988.345) and R$1.400.819 (US$841.131) respectively; and in 
the endemic period was R$ 5.848.678 (US$ 3.511.876) and R$950.619 (US$570.805), 
with human resources being responsible for the majority of costs in both peri-
ods (83 and 86%, respectively). Capital costs for both periods were R$683,315 
(U.S.$410,301), with a high cost share for transportation (80%) and infrastructure 
(13%) components. The Municipal health department was responsible for 83% 
of total costs, followed by state (13%), and federal (3%) levels. ConClusions: 
Although the estimated costs of the PMCD is under-estimated, we demonstrate a 
significant incremental costs (R$3.050,211 or U.S.$1.831.518) during the epidemic 
period. Our results can provide inputs for cost-effectiveness studies of dengue 
vaccines, which are important to support decision making regarding its introduc-
tion into public health programs.
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objeCtives: Health services utilization in poor provinces in Argentina is poorly 
known, due to data poor environments. We utilized a population based health care 
survey to analyzed the ecology of medical care, and to estimate self reported health 
care services utilization (SRHCU) patterns among adults (≥ 18 years old). Methods: 
A health Survey was performed, with probabilistic, stratified, polyetapic sampling, 
adding health utilization questions to the National Risk Factor Survey of Argentina 
(ENFR 2009) questionnaire. We obtained SRHCU stratified as ambulatory visits, 
emergency, hospitalizations, stratified into age, sex, rural, urban, health status and 
prior health problem. Analysis was performed with SPSS 17, 95%CI for single pro-
portions was obtained. Results: Among 2064 persons that responded de survey, 
78,9% were urban-21,1% rural, 41,2% males, mean age was 39,9% (SD 15,8) years 
old, age range 18-93. The General Health Status was regular or bad (16,08%) (95%CI 
14,5-17,7%). Likert scale of health status provided Mean = 86,65 (SD 104,35); Median 
80 (25P = 70; 75P = 90). Acute illness events in prior 4 weeks occurred in 24,8% (95%CI 
22,9-26,7%). 70,4% had an ambulatory visit in the prior 6 months (95%CI 68,4-72,4%), 
while, in prior month 17,0% (95%CI 15,4-18,7%) consulted a physician office [gen-
eralist 10,36% (95%CI 9,1-11,7%) and 6,7% specialist (95%CI 5,6-7,8%)]. Office visits 
rate was 261 per 100 persons per year [increased with age 65+ (305), regular or bad 
health (458), and rurality (289), decreased for males (197)]. Emergency visits occurred 
in 106 persons (5,1%) (95%CI 4,18-6,09%); Hospitalization was 10,6% during prior 
year (95%CI 9,3-11,9%), 78% admitted once and 20% readmitted to the hospital in 
the same period. ConClusions: Results provide an estimate of SRHCU data, and 
show lower ambulatory and emergency visit rates, while hospitalization admis-
sions and readmissions is similar to other ecology of medical care studies in other 
areas of the world.
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objeCtivos: Revisar la respuesta que aportan diferentes analistas a la pre-
gunta: ¿qué es lo que obtenemos del sistema sanitario (SS)? MetodologíAs: 
Se han revisado las propuestas de la OMS, la OCDE y el enfoque del NHS bri-
tánico. También las aproximaciones de investigadores como D. Cutler y J. Puig-
Junoy. ResultAdos: La OMS combina diferentes dimensiones: resultados en 
salud, equidad, equilibrio financiero y respuesta del sistema sanitario, obteniendo 
un indicador de medida absoluta y proponiendo dos índices relativos de efi-
ciencia: uno relacionado con el nivel de esperanza de vida ajustada por inca-
pacidad y otro que valora la eficiencia del SS en general. En la OCDE consideran 
que debe adjudicarse la prioridad a la medición de la relación costo-efectividad. 
Actualmente sus esfuerzos se orientan a la búsqueda de indicadores de calidad. 
El tercer enfoque estudia la variación de la productividad en el seno del NHS, 
definida como el output obtenido en relación con los inputs utilizados. Se con-
sidera que la efectividad no puede determinarse dado el grado de incertidumbre 
con respecto a los efectos específicos del SS y aboga por ponderar los resultados 
con medidas de calidad. Cutler et al obtuvieron un valor de $19.900 como coste 
por año de vida ganado (C/AVG) en el período 1960-2000 en EEUU, asumiendo que 
el SS es el responsable de la mitad del resultado. Puig-Junoy y Merino-Castelló 
estudiaron para el período 1960-2001 la productividad marginal del gasto sani-
tario en España y obtuvieron un C/AVG entre 10.045 y 12.937. ConClusiones: 
No hay consenso en cuanto al estudio de la efectividad del sistema sanitario. 
La indeterminación que supone la influencia de elementos ajenos al mismo en 
el resultado final supone un inconveniente importante. La incorporación de la 
calidad puede ayudar a superar, en parte, este problema.
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objeCtivos: Determinar las diferencias del trabajo en equipo en salas de cirugía 
entre un hospital privado y uno público de Bogotá, D.C. MetodologíAs: Estudio 
observacional analítico. Muestra: n= 90 equipos de cirugía, 49 de hospital privado 
(54%) y 41 de hospital público (46%). Criterios de inclusión: Equipos de cirugía 
general de hospitales de tercer nivel de complejidad de la ciudad de Bogotá, D.C. 
and Prevention (NCC MERP) severity scale. Results: When the list of triggers was 
used for the review of AE case reports, 61 triggers were identified in 167 (50.2%) 
cases. Transfusion / use of blood products (15%), infection of any kind (6.9%) were 
the commonly noted triggers in the critical care module. In the surgical module, 
return to surgery (6%) and occurrence of any post surgical complication (6%) were 
predominantly noted. In the medication module, repeated request for lab inves-
tigations (13.2%), use of laxatives (13.2%), pyrexia (10.8%), use of nebuliser/steam 
inhalation (7.5%), use of analgesics (6.6%) and anti-emetics (5.7%) were commonly 
noted. When the harm was studied category E was 24.9% followed by Category F- 
13.8%. ConClusions: The developed trigger list was able to flag 167 case profiles 
with potential adverse events. This tool has potential application in reviewing the 
cases for adverse events.
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objeCtives: To identify the most appropriate dosage regimen of pralidoxime that 
can be recommended for the management of OP poisoning. Methods: An open 
labeled cross-sectional, nonrandomized observational study was carried out in 
emergency wards of tertiary care hospital. A total of 256 OP poisoned patients were 
admitted between 2009 to 2013. The basic demographical, clinical characteristics 
and severity were assessed at admission. Based on the pralidoxime dosage regi-
men patients were categorized into 4 different groups viz. control, intermittent, 
500mg/ hour, 1g/ hour groups. The clinical outcome analyzed in terms of hospi-
talization days, ventilatory days, total atropine required, and incidence of inter-
mediate syndrome and outcome were assessed for comparison with pralidoxime 
regimen Results: The results showed that majority of OP poisoned patients were 
in the age group of 21-30 years, and males predominated the females (2.3:1). Clinical 
Severity assessment of these patients showed that most of them had moderate to 
high severity. Outcome analysis showed that patients of continuous infusion of 
pralidoxime had significantly improved recovery rate with least sequel and fatal-
ity rate. The incidence of intermediate syndrome, number of ventilation days, total 
atropine requirement, number of hospitalization days and mortality rate signifi-
cantly reduced in continuous infusion group. ConClusions: Continuous infusion 
of pralidoxime at 500 mg/hour resulted in significantly better clinical outcome than 
other dosing regimens and not associated with adverse derug reactions.
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objeCtives: To ascertain if the Brazilian HTA body CONITEC, which replaced CITEC 
in December 2011, is delivering on Ministry of Health (MoH) promises of transpar-
ency and set assessment timelines whilst adopting mandatory evidence require-
ments for new biologic drug funding decisions via the Unified Healthcare System 
(SUS). Methods: Secondary research based on CONITEC’s final reimbursement 
recommendation reports, evaluating existing and sponsor submitted data. These 
reports include deliberations from a plenary assembly of representatives from the 
MoH, drug regulator ANVISA and supplementary health regulator ANS, as well as 
public consultation contributions. Results: CONITEC has delivered on transpar-
ency with publications of the rationale behind each of its recommendations, thus 
enabling pharmaceutical firms to understand how to respond. The 180 day initial 
analysis phase deadline is being met but evaluation of the implementation phase 
timeline is premature. Out of the final recommendations published to date for bio-
logics, about 40% correspond to a funding rejection. Biologic medicines have been 
denied funding from psoriasis to wet AMD due to lack of cost-effectiveness as well 
as efficacy and safety studies of short duration and small patient populations. The 
rejection of everolimus for a rare brain tumour shows that orphan drugs are not 
being treated differently. Positive endorsements of biologics from breast cancer to 
rheumatoid arthritis come with recommendations of significant price cuts and crea-
tion of clinical guidelines. ConClusions: Manufacturers are struggling to adjust to 
evidence requirements needed in supporting funding applications for new biologics, 
including orphan drugs. Transparency is evident in CONITEC’s analysis phase but is 
absent after a positive recommendation, when the MoH ascertains how the medi-
cine will be offered by SUS. Nonetheless, this is an advance compared to the CITEC 
process, whereby decisions were not made public and there were no clear timelines.
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The burden of dengue is significant in Brazil. Between 2002 and 2010 approxi-
mately four million probable dengue cases were reported, with significant epi-
demics in 2002, 2008 and 2010. It is expected that a dengue vaccine, currently 
under phase 3 clinical trials, will reduce the number of cases, costs of the disease 
and costs of dengue prevention and control programs, in particular during epi-
demic peaks. objeCtives: Estimate the costs of dengue control program (PMCD) 
in the municipality of Goiânia-GO, Brazil. Methods: We conducted a retrospec-
tive analysis, considering epidemic (October/2009-April/2010), and endemic (May-
September/2010) periods of dengue transmission. The public health care system 
